IRIS Accounts Production v25.1.0.734 05004312 Board of Directors 1.4.23 31.3.24 31.3.24 Medium entities true false true true false false true true false These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. 'A' Ordinary 0.01000 'B' Ordinary 0.01000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh050043122023-03-31050043122024-03-31050043122023-04-012024-03-31050043122022-03-31050043122022-04-012023-03-31050043122023-03-3105004312ns15:EnglandWales2023-04-012024-03-3105004312ns14:PoundSterling2023-04-012024-03-3105004312ns10:Director12023-04-012024-03-3105004312ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3105004312ns10:MediumEntities2023-04-012024-03-3105004312ns10:Audited2023-04-012024-03-3105004312ns10:Medium-sizedCompaniesRegimeForDirectorsReport2023-04-012024-03-3105004312ns10:Medium-sizedCompaniesRegimeForAccounts2023-04-012024-03-3105004312ns10:FullAccounts2023-04-012024-03-3105004312ns10:OrdinaryShareClass12023-04-012024-03-3105004312ns10:OrdinaryShareClass22023-04-012024-03-3105004312ns10:Director22023-04-012024-03-3105004312ns10:CompanySecretary12023-04-012024-03-3105004312ns10:RegisteredOffice2023-04-012024-03-3105004312ns5:CurrentFinancialInstruments2024-03-3105004312ns5:CurrentFinancialInstruments2023-03-3105004312ns5:ShareCapital2024-03-3105004312ns5:ShareCapital2023-03-3105004312ns5:RetainedEarningsAccumulatedLosses2024-03-3105004312ns5:RetainedEarningsAccumulatedLosses2023-03-3105004312ns5:ShareCapital2022-03-3105004312ns5:RetainedEarningsAccumulatedLosses2022-03-3105004312ns5:RetainedEarningsAccumulatedLosses2022-04-012023-03-3105004312ns5:RetainedEarningsAccumulatedLosses2023-04-012024-03-310500431212023-04-012024-03-3105004312ns15:UnitedKingdom2023-04-012024-03-3105004312ns15:UnitedKingdom2022-04-012023-03-3105004312ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2023-04-012024-03-3105004312ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2022-04-012023-03-3105004312ns5:OwnedAssets2023-04-012024-03-3105004312ns5:OwnedAssets2022-04-012023-03-3105004312ns5:HirePurchaseContracts2023-04-012024-03-3105004312ns5:HirePurchaseContracts2022-04-012023-03-3105004312ns10:OrdinaryShareClass12022-04-012023-03-3105004312ns5:FurnitureFittings2023-03-3105004312ns5:MotorVehicles2023-03-3105004312ns5:FurnitureFittings2023-04-012024-03-3105004312ns5:MotorVehicles2023-04-012024-03-3105004312ns5:FurnitureFittings2024-03-3105004312ns5:MotorVehicles2024-03-3105004312ns5:FurnitureFittings2023-03-3105004312ns5:MotorVehicles2023-03-3105004312ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3105004312ns5:WithinOneYearns5:CurrentFinancialInstruments2023-03-3105004312ns5:Non-currentFinancialInstruments2024-03-3105004312ns5:Non-currentFinancialInstruments2023-03-3105004312ns5:DeferredTaxation2023-03-3105004312ns5:DeferredTaxation2023-04-012024-03-3105004312ns5:DeferredTaxation2024-03-3105004312ns10:OrdinaryShareClass12024-03-3105004312ns10:OrdinaryShareClass22024-03-31
REGISTERED NUMBER: 05004312 (England and Wales)






















H2H Pharmacy Limited

Strategic Report, Report of the Directors and

Financial Statements for the Year Ended 31 March 2024






H2H Pharmacy Limited (Registered number: 05004312)






Contents of the Financial Statements
for the year ended 31 March 2024




Page

Company Information 1

Strategic Report 2

Report of the Directors 3

Report of the Independent Auditors 4

Statement of Comprehensive Income 7

Balance Sheet 8

Statement of Changes in Equity 9

Notes to the Financial Statements 10


H2H Pharmacy Limited

Company Information
for the year ended 31 March 2024







DIRECTORS: B Dhariwal
Mrs S M K Dhariwal





SECRETARY: Mrs S M K Dhariwal





REGISTERED OFFICE: Sovereign House
1-2 Bingham Road
Sittingbourne
Kent
ME10 3SU





REGISTERED NUMBER: 05004312 (England and Wales)





AUDITORS: Smailes Goldie
Chartered Accountants
Statutory Auditor
Regent's Court
Princess Street
Hull
East Yorkshire
HU2 8BA

H2H Pharmacy Limited (Registered number: 05004312)

Strategic Report
for the year ended 31 March 2024

The directors present their strategic report for the year ended 31 March 2024.

REVIEW OF BUSINESS
The company has experienced a reasonable year of trading. The director believes the position outlined in note 17 will have a material impact on trading and the company will achieve stronger results in future years.

The financial key performance indicator for the company is detailed below:

2024 2023
Gross profit margin 3.9% 3.9%

PRINCIPAL RISKS AND UNCERTAINTIES
The directors believe that there is little risk and uncertainty facing the company given the services it provides and the industry in which it operates.

FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES
The company is at risk from fluctuating interest rates since its cash balances are the only form of interest bearing assets, on which they earn interest at the banks floating rate.

ON BEHALF OF THE BOARD:





B Dhariwal - Director


13 December 2024

H2H Pharmacy Limited (Registered number: 05004312)

Report of the Directors
for the year ended 31 March 2024

The directors present their report with the financial statements of the company for the year ended 31 March 2024.

PRINCIPAL ACTIVITY
The principal activity of the company in the year under review was that of the provision of pharmacy services.

DIVIDENDS
Interim dividends of £1,007,600 were paid during the year. The directors do not recommend the payment of a final dividend.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 April 2023 to the date of this report.

B Dhariwal
Mrs S M K Dhariwal

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

AUDITORS
The auditors, Smailes Goldie, will be proposed for re-appointment in accordance with section 485 of the Companies Act 2006.

ON BEHALF OF THE BOARD:





B Dhariwal - Director


13 December 2024

Report of the Independent Auditors to the Members of
H2H Pharmacy Limited

Opinion
We have audited the financial statements of H2H Pharmacy Limited (the 'company') for the year ended 31 March 2024 which comprise the Statement of Comprehensive Income, Balance Sheet, Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 31 March 2024 and of its profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of
H2H Pharmacy Limited


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page three, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, including the Companies Act 2006, tax legislation, data protection, anti-bribery, employment, environmental and health and safety legislation. An understanding of these laws and regulations and the extent of compliance was obtained through discussion with management and inspecting legal and regulatory correspondence.

We assessed the susceptibility of the company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by making enquiries of management and considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates were
indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

Report of the Independent Auditors to the Members of
H2H Pharmacy Limited

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation;
- enquiring of management as to actual and potential litigation and claims; and
- reviewing correspondence with relevant regulators and the company's legal advisors.

Due to the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission, or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Michael Stocks ACA (Senior Statutory Auditor)
for and on behalf of Smailes Goldie
Chartered Accountants
Statutory Auditor
Regent's Court
Princess Street
Hull
East Yorkshire
HU2 8BA

13 December 2024

H2H Pharmacy Limited (Registered number: 05004312)

Statement of Comprehensive Income
for the year ended 31 March 2024

2024 2023
Notes £    £   

TURNOVER 4 56,006,664 49,979,272

Cost of sales 53,815,625 48,044,485
GROSS PROFIT 2,191,039 1,934,787

Administrative expenses 1,298,502 1,203,029
892,537 731,758

Other operating income 716,771 -
OPERATING PROFIT 6 1,609,308 731,758

Interest receivable and similar income 26,153 1,196
1,635,461 732,954

Interest payable and similar expenses 7 2,342 1,875
PROFIT BEFORE TAXATION 1,633,119 731,079

Tax on profit 8 419,678 139,541
PROFIT FOR THE FINANCIAL YEAR 1,213,441 591,538

OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME
FOR THE YEAR

1,213,441

591,538

H2H Pharmacy Limited (Registered number: 05004312)

Balance Sheet
31 March 2024

2024 2023
Notes £    £    £   
FIXED ASSETS
Tangible assets 10 117,019 109,704

CURRENT ASSETS
Debtors 11 5,838,771 5,339,527
Cash at bank 1,722,554 2,395,949
7,561,325 7,735,476
CREDITORS
Amounts falling due within one year 12 6,372,544 6,759,224
NET CURRENT ASSETS 1,188,781 976,252
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,305,800

1,085,956

PROVISIONS FOR LIABILITIES 13 27,240 13,237
NET ASSETS 1,278,560 1,072,719

CAPITAL AND RESERVES
Called up share capital 14 120 120
Retained earnings 1,278,440 1,072,599
SHAREHOLDERS' FUNDS 1,278,560 1,072,719

The financial statements were approved by the Board of Directors and authorised for issue on 13 December 2024 and were signed on its behalf by:





B Dhariwal - Director


H2H Pharmacy Limited (Registered number: 05004312)

Statement of Changes in Equity
for the year ended 31 March 2024

Called up
share Retained Total
capital earnings equity
£    £    £   
Balance at 1 April 2022 120 2,489,061 2,489,181

Changes in equity
Dividends - (2,008,000 ) (2,008,000 )
Total comprehensive income - 591,538 591,538
Balance at 31 March 2023 120 1,072,599 1,072,719

Changes in equity
Dividends - (1,007,600 ) (1,007,600 )
Total comprehensive income - 1,213,441 1,213,441
Balance at 31 March 2024 120 1,278,440 1,278,560

H2H Pharmacy Limited (Registered number: 05004312)

Notes to the Financial Statements
for the year ended 31 March 2024

1. STATUTORY INFORMATION

H2H Pharmacy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Accounting convention
These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling , which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

Financial Reporting Standard 102 - reduced disclosure exemptions
The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

the requirements of Section 7 Statement of Cash Flows;
the requirement of paragraph 33.7.

Going concern
At the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements. In addition, the parent company has confirmed that it will provide support to the subsidiary as is required.

Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

H2H Pharmacy Limited (Registered number: 05004312)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of
depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery25% reducing balance
Fixtures, fittings & equipment33% reducing balance
Motor vehicles33% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

H2H Pharmacy Limited (Registered number: 05004312)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

2. ACCOUNTING POLICIES - continued

Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset , with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

H2H Pharmacy Limited (Registered number: 05004312)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

2. ACCOUNTING POLICIES - continued

Financial instruments (continued)

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payment ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Other financial liabilities
Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.

Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value though profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.

Derecognition of financial liabilities
Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

H2H Pharmacy Limited (Registered number: 05004312)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

2. ACCOUNTING POLICIES - continued

Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

3. JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

4. TURNOVER

The turnover and profit before taxation are attributable to the one principal activity of the company.

An analysis of turnover by geographical market is given below:

2024 2023
£    £   
United Kingdom 56,006,664 49,979,272
56,006,664 49,979,272

5. EMPLOYEES AND DIRECTORS
2024 2023
£    £   
Wages and salaries 491,922 401,076
Social security costs 45,496 39,881
Other pension costs 9,169 20,766
546,587 461,723

H2H Pharmacy Limited (Registered number: 05004312)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

5. EMPLOYEES AND DIRECTORS - continued

The average number of employees during the year was as follows:
2024 2023

Directors 2 2
Administration 1 1
Production 15 13
18 16

2024 2023
£    £   
Directors' remuneration - -

The number of directors to whom retirement benefits were accruing was as follows:

Money purchase schemes - 1

6. OPERATING PROFIT

The operating profit is stated after charging/(crediting):

2024 2023
£    £   
Depreciation - owned assets 43,997 29,508
Profit on disposal of fixed assets (41,119 ) (27,523 )
Auditors' remuneration 16,900 16,100

7. INTEREST PAYABLE AND SIMILAR EXPENSES
2024 2023
£    £   
Other interest 2,342 774
Hire purchase - 1,101
2,342 1,875

8. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
2024 2023
£    £   
Current tax:
UK corporation tax 405,675 136,922

Deferred tax 14,003 2,619
Tax on profit 419,678 139,541

H2H Pharmacy Limited (Registered number: 05004312)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

9. DIVIDENDS
2024 2023
£    £   
'A' Ordinary shares of £0.01 each
Interim 1,007,600 2,008,000

10. TANGIBLE FIXED ASSETS
Fixtures
and Motor
fittings vehicles Totals
£    £    £   
COST
At 1 April 2023 11,625 121,218 132,843
Additions - 138,859 138,859
Disposals - (121,218 ) (121,218 )
At 31 March 2024 11,625 138,859 150,484
DEPRECIATION
At 1 April 2023 9,671 13,468 23,139
Charge for year 651 43,346 43,997
Eliminated on disposal - (33,671 ) (33,671 )
At 31 March 2024 10,322 23,143 33,465
NET BOOK VALUE
At 31 March 2024 1,303 115,716 117,019
At 31 March 2023 1,954 107,750 109,704

11. DEBTORS
2024 2023
£    £   
Amounts falling due within one year:
Trade debtors 4,914,467 4,963,959
Other debtors 252,000 2,000
Prepayments and accrued income 230,532 373,568
5,396,999 5,339,527

Amounts falling due after more than one year:
Other debtors 441,772 -

Aggregate amounts 5,838,771 5,339,527

H2H Pharmacy Limited (Registered number: 05004312)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

12. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 4,753,636 4,727,632
Amounts owed to group undertakings 1,145,428 1,828,072
Corporation tax 405,675 136,922
Social security and other taxes 11,722 10,121
VAT 33,511 34,249
Other creditors 1,972 1,628
Accruals and deferred income 20,600 20,600
6,372,544 6,759,224

13. PROVISIONS FOR LIABILITIES
2024 2023
£    £   
Deferred tax 27,240 13,237

Deferred
tax
£   
Balance at 1 April 2023 13,237
Charge to Statement of Comprehensive Income during year 14,003
Balance at 31 March 2024 27,240

Deferred tax relates to accelerated capital allowances. The net deferred tax liability expected to reverse in the next financial year is £6,912.

14. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
24 'A' Ordinary £0.01 - -
11,976 'B' Ordinary £0.01 120 120
120 120

15. ULTIMATE CONTROLLING PARTY

The company is 100% owned by Lime Groves (Sittingbourne) Limited, a company in which B Dhariwal is the majority shareholder.